About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Expert Review of Vaccines
›
top-articles
Expert Review of Vaccines
5.2
(top 5%)
impact factor
2.1K
(top 10%)
papers
73.9K
(top 5%)
citations
107
(top 5%)
h
-index
5.8
(top 5%)
impact factor
2.9K
all documents
78.6K
doc citations
156
(top 5%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Virus-like particles in vaccine development
Expert Review of Vaccines
2010
671
2
CpG DNA as a vaccine adjuvant
Expert Review of Vaccines
2011
670
3
Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications
Expert Review of Vaccines
2015
636
4
Vaccines for fish in aquaculture
Expert Review of Vaccines
2005
583
5
The fundamental link between pneumococcal carriage and disease
Expert Review of Vaccines
2012
519
6
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses
Expert Review of Vaccines
2010
443
7
Poultry coccidiosis: recent advancements in control measures and vaccine development
Expert Review of Vaccines
2006
436
8
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Expert Review of Vaccines
2007
432
9
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Expert Review of Vaccines
2017
353
10
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Expert Review of Vaccines
2012
281
11
Virus-like particles: flexible platforms for vaccine development
Expert Review of Vaccines
2007
280
12
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Expert Review of Vaccines
2011
280
13
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Expert Review of Vaccines
2002
265
14
Technologies for enhanced efficacy of DNA vaccines
Expert Review of Vaccines
2012
265
15
The history of MF59
®
adjuvant: a phoenix that arose from the ashes
Expert Review of Vaccines
2013
254
16
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
Expert Review of Vaccines
2007
245
17
Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines
Expert Review of Vaccines
2009
241
18
Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice
Expert Review of Vaccines
2008
234
19
Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation
Expert Review of Vaccines
2007
233
20
Nanoparticles and microparticles as vaccine-delivery systems
Expert Review of Vaccines
2007
232
21
Molecular mechanisms for enhanced DNA vaccine immunogenicity
Expert Review of Vaccines
2016
231
22
Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529
Expert Review of Vaccines
2003
222
23
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
Expert Review of Vaccines
2013
214
24
Microparticles as vaccine adjuvants and delivery systems
Expert Review of Vaccines
2003
205
25
Yellow fever vaccine
Expert Review of Vaccines
2005
202
26
Repeated annual influenza vaccination and vaccine effectiveness: review of evidence
Expert Review of Vaccines
2017
201
27
Chikungunya virus and prospects for a vaccine
Expert Review of Vaccines
2012
197
28
Epaxal
®
: a virosomal vaccine to prevent hepatitis A infection
Expert Review of Vaccines
2008
196
29
The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection
Expert Review of Vaccines
2017
194
30
MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile
Expert Review of Vaccines
2003
192
31
Trends in vaccine adjuvants
Expert Review of Vaccines
2011
186
32
Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
Expert Review of Vaccines
2009
185
33
Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments
Expert Review of Vaccines
2009
184
34
Vaccine adjuvant uses of poly-IC and derivatives
Expert Review of Vaccines
2015
183
35
Opportunities and challenges of developing thermostable vaccines
Expert Review of Vaccines
2009
181
36
Impact of the Delta variant on vaccine efficacy and response strategies
Expert Review of Vaccines
2021
177
37
Vaccination against foot-and-mouth disease virus: strategies and effectiveness
Expert Review of Vaccines
2009
174
38
New hepatitis B vaccine formulated with an improved adjuvant system
Expert Review of Vaccines
2007
171
39
Effect of vaccine administration modality on immunogenicity and efficacy
Expert Review of Vaccines
2015
171
40
Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza control
Expert Review of Vaccines
2017
170
41
The evolving history of influenza viruses and influenza vaccines
Expert Review of Vaccines
2013
168
42
EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)
Expert Review of Vaccines
2016
168
43
Cationic liposomes as vaccine adjuvants
Expert Review of Vaccines
2011
166
44
Preventing urinary tract infection: progress toward an effective
Escherichia coli
vaccine
Expert Review of Vaccines
2012
166
45
SARS vaccines: where are we?
Expert Review of Vaccines
2009
165
46
Lipid-based mRNA vaccine delivery systems
Expert Review of Vaccines
2015
165
47
Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists
Expert Review of Vaccines
2010
164
48
Restoring confidence in vaccines in the COVID-19 era
Expert Review of Vaccines
2020
160
49
Chitosan-based systems for the delivery of vaccine antigens
Expert Review of Vaccines
2009
158
50
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer
Expert Review of Vaccines
2011
158
site/software ©
exaly
; All materials licenced under
CC by-SA
.